electroCore Q3 2026 net loss narrows 61% to $1.34 million; Q3 2026 net sales rise 12% to $9.69 million

Bitget2026/11/04 21:20

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

electroCore’s third-quarter 2026 net loss narrowed 61% year over year to $1.34 million.
Quarterly revenue rose 12% to $9.7 million, driven primarily by VA sales of Quell Fibromyalgia and prescription gammaCore.
In October 2026, it submitted an FDA application seeking clearance for Quell to treat chronic chemotherapy-induced peripheral neuropathy.
Full-year 2026 revenue guidance was revised to $39 million–$42 million, replacing an outlook for growth above 30%.
Preliminary 2027 guidance calls for revenue growth of 30%–40% over 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. electroCore Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041605PRIMZONEFULLFEED9870507) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

electroCore Q3 2026 net loss narrows 61% to $1.34 million; Q3 2026 net sales rise 12% to $9.69 million

You may also like

Crypto prices